Kalia, L. V. & Lang, A. E. Parkinson’s disease. Lancet 386, 896–912 (2015).
Braak, H. et al. Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol. Aging 24, 197–211 (2003).
Pagonabarraga, J., Bejr-Kasem, H., Martinez-Horta, S. & Kulisevsky, J. Parkinson disease psychosis: from phenomenology to neurobiological mechanisms. Nat. Rev. Neurol. 20, 135–150 (2024).
Postuma, R. B. & Berg, D. Advances in markers of prodromal Parkinson disease. Nat. Rev. Neurol. 12, 622–634 (2016).
Fénelon, G. Psychosis in Parkinson’s disease: phenomenology, frequency, risk factors, and current understanding of pathophysiologic mechanisms. CNS Spectr. 13, 18–25 (2008).
Fénelon, G., Soulas, T., Zenasni, F. & De Langavant, L. C. The changing face of Parkinson’s disease-associated psychosis: a cross-sectional study based on the new NINDS–NIMH criteria. Mov. Disord. 25, 755–759 (2010).
Ffytche, D. H. et al. The psychosis spectrum in Parkinson disease. Nat. Rev. Neurol. 13, 81–95 (2017).
Lenka, A., Hegde, S., Jhunjhunwala, K. R. & Pal, P. K. Interactions of visual hallucinations, rapid eye movement sleep behavior disorder and cognitive impairment in Parkinson’s disease: a review. Parkinsonism Relat. Disord. 22, 1–8 (2016).
Bernasconi, F. et al. Theta oscillations and minor hallucinations in Parkinson’s disease reveal decrease in frontal lobe functions and later cognitive decline. Nat. Ment. Health 1, 477–488 (2023).
Lenka, A., Pagonabarraga, J., Pal, P. K., Bejr-Kasem, H. & Kulisvesky, J. Minor hallucinations in Parkinson disease: a subtle symptom with major clinical implications. Neurology 93, 259–266 (2019).
Fénelon, G., Mahieux, F., Huon, R. & Ziégler, M. Hallucinations in Parkinson’s disease: prevalence, phenomenology and risk factors. Brain 123, 733–745 (2000).
Aarsland, D. et al. Parkinson disease-associated cognitive impairment. Nat. Rev. Dis. Primers 7, 47 (2021).
Levin, J., Hasan, A. & Höglinger, G. U. Psychosis in Parkinson’s disease: identification, prevention and treatment. J. Neural Transm. 123, 45–50 (2016).
Diederich, N. J., Fénelon, G., Stebbins, G. & Goetz, C. G. Hallucinations in Parkinson disease. Nat. Rev. Neurol. 5, 331–342 (2009).
Forsaa, E. B., Larsen, J. P., Wentzel-Larsen, T. & Alves, G. What predicts mortality in Parkinson disease? A prospective population-based long-term study. Neurology 75, 1270–1276 (2010).
Galvin, J. E., Pollack, J. & Morris, J. C. Clinical phenotype of Parkinson disease dementia. Neurology 67, 1605–1611 (2006).
Marinus, J., Zhu, K., Marras, C., Aarsland, D. & van Hilten, J. J. Risk factors for non-motor symptoms in Parkinson’s disease. Lancet Neurol. 17, 559–568 (2018).
Aarsland, D., Larsen, J. P., Tandberg, E. & Laake, K. Predictors of nursing home placement in Parkinson’s disease: a population-based, prospective study. J. Am. Geriatr. Soc. 48, 938–942 (2000).
Goetz, C. G., Emre, M. & Dubois, B. Parkinson’s disease dementia: definitions, guidelines, and research perspectives in diagnosis. Ann. Neurol. 64, S81–92 (2008).
Gonzalez, M. C., Dalen, I., Maple-Grødem, J., Tysnes, O.-B. & Alves, G. Parkinson’s disease clinical milestones and mortality. npj Parkinsons Dis. 8, 58 (2022).
Lenka, A., Jhunjhunwala, K. R., Saini, J. & Pal, P. K. Structural and functional neuroimaging in patients with Parkinson’s disease and visual hallucinations: a critical review. Parkinsonism Relat. Disord. 21, 683–691 (2015).
Goetz, C. G., Vaughan, C. L., Goldman, J. G. & Stebbins, G. T. I finally see what you see: Parkinson’s disease visual hallucinations captured with functional neuroimaging. Mov. Disord. 29, 115–117 (2014).
Bhome, R., Thomas, G. E. C., Zarkali, A. & Weil, R. S. Structural and functional imaging correlates of visual hallucinations in Parkinson’s Disease. Curr. Neurol. Neurosci. Rep. 23, 287–299 (2023).
Shine, J. M., Halliday, G. M., Naismith, S. L. & Lewis, S. J. G. Visual misperceptions and hallucinations in Parkinson’s disease: dysfunction of attentional control networks? Mov. Disord. 26, 2154–2159 (2011).
Shine, J. M., O’Callaghan, C., Halliday, G. M. & Lewis, S. J. G. Tricks of the mind: visual hallucinations as disorders of attention. Prog. Neurobiol. 116, 58–65 (2014).
Shine, J. M. et al. Abnormal connectivity between the default mode and the visual system underlies the manifestation of visual hallucinations in Parkinson’s disease: a task-based fMRI study. npj Parkinsons Dis. 1, 15003 (2015).
Weil, R. S. et al. Visual dysfunction in Parkinson’s disease. Brain 139, 2827–2843 (2016).
Ravina, B. et al. Diagnostic criteria for psychosis in Parkinson’s disease: report of an NINDS, NIMH work group. Mov. Disord. 22, 1061–1068 (2007).
Pagonabarraga, J. et al. Minor hallucinations occur in drug-naive Parkinson’s disease patients, even from the premotor phase. Mov. Disord. 31, 45–52 (2016).
de Maindreville, A. D., Fénelon, G. & Mahieux, F. Hallucinations in Parkinson’s disease: a follow-up study. Mov. Disord. 20, 212–217 (2005).
Bernasconi, F. et al. Robot-induced hallucinations in Parkinson’s disease depend on altered sensorimotor processing in fronto-temporal network. Sci. Transl. Med. 13, eabc8362 (2021).
Zhong, M. et al. Aberrant gray matter volume and functional connectivity in Parkinson’s disease with minor hallucination. Front. Aging Neurosci. 14, 923560 (2022).
Bejr-kasem, H. et al. Minor hallucinations reflect early gray matter loss and predict subjective cognitive decline in Parkinson’s disease. Eur. J. Neurol. 28, 438–447 (2021).
Baik, K. et al. Functional brain networks of minor and well-structured major hallucinations in Parkinson’s disease. Mov. Disord. 39, 318–327 (2024).
Bejr-kasem, H. et al. Disruption of the default mode network and its intrinsic functional connectivity underlies minor hallucinations in Parkinson’s disease. Mov. Disord. 34, 78–86 (2019).
Finn, E. S. et al. Functional connectome fingerprinting: identifying individuals using patterns of brain connectivity. Nat. Neurosci. 18, 1664–1671 (2015).
Amico, E. & Goñi, J. The quest for identifiability in human functional connectomes. Sci. Rep. 8, 8254 (2018).
da Silva Castanheira, J., Orozco Perez, H. D., Misic, B. & Baillet, S. Brief segments of neurophysiological activity enable individual differentiation. Nat. Commun. 12, 5713 (2021).
Finn, E. S. & Rosenberg, M. D. Beyond fingerprinting: choosing predictive connectomes over reliable connectomes. NeuroImage 239, 118254 (2021).
Rosenberg, M. D. et al. A neuromarker of sustained attention from whole-brain functional connectivity. Nat. Neurosci. 19, 165–171 (2016).
Kaufmann, T. et al. Delayed stabilization and individualization in connectome development are related to psychiatric disorders. Nat. Neurosci. 20, 513–515 (2017).
Kaufmann, T. et al. Stability of the brain functional connectome fingerprint in individuals with schizophrenia. JAMA Psychiatry 75, 749–751 (2018).
Fu, Z., Liu, J., Salman, M. S., Sui, J. & Calhoun, V. D. Functional connectivity uniqueness and variability? Linkages with cognitive and psychiatric problems in children. Nat. Ment. Health 1, 956–970 (2023).
Sorrentino, P. et al. Clinical connectome fingerprints of cognitive decline. NeuroImage 238, 118253 (2021).
Stampacchia, S. et al. Fingerprints of brain disease: connectome identifiability in Alzheimer’s disease. Commun. Biol. 7, 1169 (2024).
da Silva Castanheira, J. et al. The neurophysiological brain-fingerprint of Parkinson’s disease. eBioMedicine 105, 105201 (2024).
Troisi Lopez, E. et al. Fading of brain network fingerprint in Parkinson’s disease predicts motor clinical impairment. Hum. Brain Mapp. 44, 1239–1250 (2022).
Vignando, M. et al. Mapping brain structural differences and neuroreceptor correlates in Parkinson’s disease visual hallucinations. Nat. Commun. 13, 519 (2022).
Ballanger, B. et al. Serotonin 2A receptors and visual hallucinations in Parkinson disease. Arch. Neurol. 67, 416–421 (2010).
Firbank, M. J. et al. Reduced occipital GABA in Parkinson disease with visual hallucinations. Neurology 91, e675–e685 (2018).
Pini, L., Lista, S., Griffa, A., Allali, G. & Imbimbo, B. P. Can brain network connectivity facilitate the clinical development of disease-modifying anti-Alzheimer drugs? Brain Commun. 7, fcae460 (2024).
Ramduny, J. & Kelly, C. Connectome-based fingerprinting: reproducibility, precision, and behavioral prediction. Neuropsychopharmacology 50, 114–123 (2024).
Kim, N. Y. et al. Lesions causing hallucinations localize to one common brain network. Mol. Psychiatry 26, 1299–1309 (2021).
Pagonabarraga, J. et al. Neural correlates of minor hallucinations in non-demented patients with Parkinson’s disease. Parkinsonism Relat. Disord. 20, 290–296 (2014).
Moberget, T. & Ivry, R. B. Prediction, psychosis, and the cerebellum. Biol. Psychiatry Cogn. Neurosci. Neuroimaging 4, 820–831 (2019).
Blanke, O. et al. Neurological and robot-controlled induction of an apparition. Curr. Biol. 24, 2681–2686 (2014).
Bejr-Kasem, H. et al. The role of attentional control over interference in minor hallucinations in Parkinson’s disease. Parkinsonism Relat. Disord. 102, 101–107 (2022).
Rajamani, N. et al. Deep brain stimulation of symptom-specific networks in Parkinson’s disease. Nat. Commun. 15, 4662 (2024).
Zarkali, A. et al. Changes in dynamic transitions between integrated and segregated states underlie visual hallucinations in Parkinson’s disease. Commun. Biol. 5, 928 (2022).
Huot, P. et al. Increased 5-HT2A receptors in the temporal cortex of parkinsonian patients with visual hallucinations. Mov. Disord. 25, 1399–1408 (2010).
Perry, E. K. & Perry, R. H. Acetylcholine and hallucinations: disease-related compared to drug-induced alterations in human consciousness. Brain Cogn. 28, 240–258 (1995).
Pasquini, J., Brooks, D. J. & Pavese, N. The cholinergic brain in Parkinson’s disease. Mov. Disord. Clinical Practice 8, 1012–1026 (2021).
Albert, L., Potheegadoo, J., Herbelin, B., Bernasconi, F. & Blanke, O. Numerosity estimation of virtual humans as a digital-robotic marker for hallucinations in Parkinson’s disease. Nat. Commun. 15, 1905 (2024).
Bernasconi, F. et al. Neuroscience robotics for controlled induction and real-time assessment of hallucinations. Nat. Protoc. 17, 2966–2989 (2022).
Gordon, E. M. et al. Precision functional mapping of individual human brains. Neuron 95, 791–807 (2017).
Postuma, R. B. et al. MDS clinical diagnostic criteria for Parkinson’s disease. Mov. Disord. 30, 1591–1601 (2015).
Goetz, C. G. et al. Movement Disorder Society-sponsored revision of the Unified Parkinson’s Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov. Disord. 23, 2129–2170 (2008).
Power, J. D., Barnes, K. A., Snyder, A. Z., Schlaggar, B. L. & Petersen, S. E. Spurious but systematic correlations in functional connectivity MRI networks arise from subject motion. NeuroImage 59, 2142–2154 (2012).
Power, J. D. et al. Methods to detect, characterize, and remove motion artifact in resting state fMRI. NeuroImage 84, 320–341 (2014).
Amico, E. et al. Mapping the functional connectome traits of levels of consciousness. NeuroImage 148, 201–211 (2017).
Shen, X., Tokoglu, F., Papademetris, X. & Constable, R. T. Groupwise whole-brain parcellation from resting-state fMRI data for network node identification. NeuroImage 82, 403–415 (2013).
Greve, D. N. & Fischl, B. Accurate and robust brain image alignment using boundary-based registration. NeuroImage 48, 63–72 (2009).
Yeo, B. T. T. et al. The organization of the human cerebral cortex estimated by intrinsic functional connectivity. J. Neurophysiol. 106, 1125–1165 (2011).
Amico, E. et al. The disengaging brain: dynamic transitions from cognitive engagement and alcoholism risk. NeuroImage 209, 116515 (2020).
Amico, E. & Goñi, J. Mapping hybrid functional-structural connectivity traits in the human connectome. Netw. Neurosci. 2, 306–322 (2018).
Van De Ville, D., Farouj, Y., Preti, M. G., Liégeois, R. & Amico, E. When makes you unique: temporality of the human brain fingerprint. Sci. Adv. 7, eabj0751 (2021).
Stampacchia, S. et al. Fingerprinting of brain disease: connectome identifiability in Alzheimer’s disease. Commun. Biol. 7, 1169 (2024).
McGraw, K. O. & Wong, S. P. Forming inferences about some intraclass correlation coefficients. Psychol. Methods 1, 30–46 (1996).
Birn, R. M. et al. The effect of scan length on the reliability of resting-state fMRI connectivity estimates. NeuroImage 83, 550–558 (2013).
Somandepalli, K. et al. Short-term test–retest reliability of resting state fMRI metrics in children with and without attention-deficit/hyperactivity disorder. Dev. Cogn. Neurosci. 15, 83–93 (2015).
Shehzad, Z. et al. The resting brain: unconstrained yet reliable. Cereb. Cortex 19, 2209–2229 (2009).
Shah, L. M., Cramer, J. A., Ferguson, M. A., Birn, R. M. & Anderson, J. S. Reliability and reproducibility of individual differences in functional connectivity acquired during task and resting state. Brain Behav. 6, e00456 (2016).
Noble, S., Scheinost, D. & Constable, R. T. A decade of test–retest reliability of functional connectivity: a systematic review and meta-analysis. NeuroImage 203, 116157 (2019).
Cicchetti, D. V. & Sparrow, S. A. Developing criteria for establishing interrater reliability of specific items: applications to assessment of adaptive behavior. Am. J. Ment. Defic. 86, 127–137 (1981).
Xia, M., Wang, J. & He, Y. BrainNet viewer: a network visualization tool for human brain connectomics. PLoS ONE 8, e68910 (2013).
Fernández de Bobadilla, R. et al. Parkinson’s disease-cognitive rating scale: psychometrics for mild cognitive impairment. Mov. Disord. 28, 1376–1383 (2013).
Markello, R. D. et al. neuromaps: structural and functional interpretation of brain maps. Nat Methods 19, 1472–1479 (2022).
Savli, M. et al. Normative database of the serotonergic system in healthy subjects using multi-tracer PET. NeuroImage 63, 447–459 (2012).
Kaller, S. et al. Test–retest measurements of dopamine D1-type receptors using simultaneous PET/MRI imaging. Eur. J. Nucl. Med. Mol. Imaging 44, 1025–1032 (2017).
Alakurtti, K. et al. Long-term test–retest reliability of striatal and extrastriatal dopamine D2/3 receptor binding: study with [11C]raclopride and high-resolution PET. J. Cereb. Blood Flow Metab. 35, 1199–1205 (2015).
Dukart, J. et al. Cerebral blood flow predicts differential neurotransmitter activity. Sci. Rep. 8, 4074 (2018).
Naganawa, M. et al. First in human assessment of the novel M1 muscarinic acetylcholine receptor PET radiotracer 11C-LSN3172176. J. Nucl. Med. https://doi.org/10.2967/jnumed.120.246967 (2020).
Hillmer, A. T. et al. Imaging of cerebral α4β2* nicotinic acetylcholine receptors with (−)−[18F]Flubatine PET: implementation of bolus plus constant infusion and sensitivity to acetylcholine in human brain. NeuroImage 141, 71–80 (2016).
R: a language and environment for statistical computing. https://www.R-project.org/ (R Core Team, 2020).
MATLAB (The MathWorks Inc., 2022).
Frossard, J. & Renaud, O. Permutation tests for regression, ANOVA, and comparison of signals: the permuco package. J. Stat. Soft. 99, 1–32 (2021).
Sareen, E. et al. Exploring MEG brain fingerprints: evaluation, pitfalls, and interpretations. NeuroImage 240, 118331 (2021).
Leave a Reply